



# ***Alpa Laboratories Ltd.***

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

12<sup>th</sup> November, 2019

To,  
Listing Department, -  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001

To,  
Listing Department,  
National Stock Exchange of India Limited.  
'Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Reference: Scrip Code: ALPA ; ISIN: INE385I01010**

Dear Sir/ Madam,

This is with reference to our letter dated 31<sup>st</sup> October, 2019 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter and Half Year ended on 30<sup>th</sup> September, 2019 with Limited Review Report from the Statutory Auditor of the Company.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

**For ALPA LABORATORIES LIMITED**

*Megha Neema*

Megha Neema  
Company Secretary





**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE  
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE  
SEBI LODR REGULATIONS, 2015**

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **September 30, 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of

**ANURADHA RATNAPARKHI & ASSOCIATES.**

Chartered Accountants

Firm Registration No.023451C

*Anuradha Ratnaparkhi*  
**ANURADHA RATNAPARKHI**

Proprietor

Membership Number: 075412

UDIN-19075412AAAAAW7325



Place: Indore

Date: 12<sup>th</sup> November, 2019

# ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE  
(M.P.) 453446

Financial Results for Quarter ended 30th September 2019

(Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone and Consolidated						
Particular	Standalone Results					
	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-19	30-Jun-19	30-Sep-18	30-Sep-19	30-Sep-18	31-Mar-19
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2,351.28	2,016.71	1,590.77	4,367.99	3,291.64	7,798.80
b) Other Income	35.33	67.94	95.69	103.27	206.92	506.52
<b>1. Total income from operations (net) (a+b)</b>	<b>2,386.60</b>	<b>2,084.65</b>	<b>1,686.45</b>	<b>4,471.25</b>	<b>3,498.56</b>	<b>8,305.32</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,494.56	1,320.89	1,173.22	2,815.45	2,029.56	4,645.84
b) Purchases of stock-in-trade	44.21	50.20	17.50	94.41	38.17	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	19.47	(121.27)	(263.17)	(101.80)	(127.06)	152.61
d) Employee benefits expenses	279.69	281.34	274.44	561.03	536.65	1,204.10
e) Finance costs	4.49	8.96	20.49	13.45	39.73	56.87
f) Depreciation and amortization expenses	27.26	25.09	28.35	52.35	55.98	109.57
g) Other expenses						
Manufacturing & Operating	116.30	98.82	102.85	215.12	202.25	425.85
Others	302.79	243.04	270.43	545.83	484.50	1,185.37
<b>Total expenses</b>	<b>2,288.77</b>	<b>1,907.07</b>	<b>1,624.10</b>	<b>4,195.84</b>	<b>3,259.79</b>	<b>7,864.87</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>97.83</b>	<b>177.58</b>	<b>62.35</b>	<b>275.41</b>	<b>238.78</b>	<b>440.45</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>97.83</b>	<b>177.58</b>	<b>62.35</b>	<b>275.41</b>	<b>238.78</b>	<b>440.45</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	(125.00)
Deffered tax	-	-	-	-	-	(59.02)
Tax Related to Earlier Years	-	-	-	-	18.73	16.71
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>97.83</b>	<b>177.58</b>	<b>62.35</b>	<b>275.41</b>	<b>257.51</b>	<b>273.14</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	0.30	1.37	-	1.67	-	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-	-	-
<b>9. Total comprehensive income for the period (7+8)</b>	<b>98.14</b>	<b>178.95</b>	<b>62.35</b>	<b>277.09</b>	<b>257.51</b>	<b>266.54</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity (excluding revaluation reserve)</b>	-	-	-	-	-	<b>8,486.87</b>
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>0.47</b>	<b>0.85</b>	<b>0.30</b>	<b>1.32</b>	<b>1.22</b>	<b>1.27</b>



For ALPA LABORATORIES LIMITED  
  
**RAKESH CHAWLA**  
 MANAGING DIRECTOR  
 DIN NO.00520411



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED  
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE  
SEBI LODR REGULATIONS, 2015**

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **September 30, 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of

**ANURADHA RATNAPARKHI & ASSOCIATES.**

Chartered Accountants

Firm Registration No.023451C

*Anuradha Ratnaparkhi*  
ANURADHA RATNAPARKHI

Proprietor

Membership Number: 075412

UDIN-19075412AAAAAW7325



Place: Indore

Date: 12<sup>th</sup> November, 2019

Particular	Consolidated Results					
	Quarter Ended			Half Year Ended		Year Ended
	30-Sep-19	30-Jun-19	30-Sep-18	30-Sep-19	30-Sep-18	31-Mar-19
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2,351.28	2,016.71	1,590.77	4,367.99	3,291.64	7,798.80
b) Other Income	26.72	70.58	113.96	97.30	230.06	529.88
<b>1. Total income from operations (net) (a+b)</b>	<b>2,377.99</b>	<b>2,087.29</b>	<b>1,704.73</b>	<b>4,465.28</b>	<b>3,521.70</b>	<b>8,328.68</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,494.56	1,320.89	1,173.30	2,815.45	2,029.56	4,645.84
b) Purchases of stock-in-trade	44.21	50.20	17.50	94.41	38.17	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	19.47	(121.27)	(263.17)	(101.80)	(127.06)	152.61
d) Employee benefits expenses	279.69	281.34	274.54	561.03	536.65	1,204.10
e) Finance costs	4.49	8.96	21.60	13.45	39.73	56.87
f) Depreciation and amortization expenses	77.82	75.66	78.91	153.48	157.10	311.82
g) Other expenses						
Manufacturing & Operating	116.30	98.82	102.86	215.12	202.25	425.85
Others	302.81	251.45	279.21	554.26	484.74	1,193.08
<b>Total expenses</b>	<b>2,339.35</b>	<b>1,966.05</b>	<b>1,684.77</b>	<b>4,305.40</b>	<b>3,361.16</b>	<b>8,074.83</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>38.65</b>	<b>121.24</b>	<b>19.96</b>	<b>159.89</b>	<b>160.54</b>	<b>253.85</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>38.65</b>	<b>121.24</b>	<b>19.96</b>	<b>159.89</b>	<b>160.54</b>	<b>253.85</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	(125.00)
Deffered tax	-	-	-	-	-	(59.02)
Tax Related to Earlier Years	-	-	-	-	18.73	9.56
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>38.65</b>	<b>121.24</b>	<b>19.96</b>	<b>159.89</b>	<b>179.27</b>	<b>79.39</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	0.30	1.37	-	1.67	-	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-	-	-
<b>9. Total comprehensive income for the period (7+8)</b>	<b>38.95</b>	<b>122.61</b>	<b>19.96</b>	<b>161.56</b>	<b>179.27</b>	<b>72.79</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity ( excluding revaluation reserve)</b>	-	-	-	-	-	<b>7,723.64</b>
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>0.19</b>	<b>0.58</b>	<b>0.09</b>	<b>0.77</b>	<b>0.85</b>	<b>0.35</b>

**Notes -**

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules 2015 and Companies ( Indian Accounting Standards ) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.



For ALPA LABORATORIES LIMITED

PARESH CHAWLA  
MANAGING DIRECTOR  
DIN NO.00520411

**II. Statement of Assets and Liabilities - Standalone and Consolidated**

Particulars	Standalone Results		Consolidated Results	
	30-Sep-19	31-Mar-19	30-Sep-19	31-Mar-19
	Unaudited	Audited	Unaudited	Audited
<b>ASSETS</b>				
<b>Non-current assets</b>				
(a) Property Plant and Equipment	593.20	576.13	593.20	576.13
(b) Capital Work-in-progress	60.06	11.78	60.06	11.78
(c) Investments in subsidiaries, associates and joint venture	1,094.39	1,083.85	-	-
(d) Intangible Assets	-	-	101.13	202.25
(e) Financial Assets				
(i) Investment	1,745.47	1,840.81	1,745.47	1,840.81
(i) Other Financial Assets	30.70	43.02	30.70	43.02
(f) Deferred tax assets (net)	17.10	17.10	17.10	17.10
<b>Sub-total - Non-current assets</b>	<b>3,540.92</b>	<b>3,572.69</b>	<b>2,547.66</b>	<b>2,691.09</b>
<b>Current Assets</b>				
(a) Inventories	1,214.74	1,403.87	1,214.74	1,403.87
(b) Financial Assets				
(i) Investment	3,542.88	2,996.10	3,542.88	2,996.10
(ii) Trade receivables	2,521.88	2,980.94	2,521.88	2,999.80
(iii) Cash and Cash Equivalents	252.83	13.48	254.65	14.91
(iv) Bank Balances other than (iii) above	119.50	75.00	119.50	75.00
(v) Short term loans & advances	406.38	503.50	494.00	594.61
(vi) Others	161.56	328.69	186.85	312.25
(c) Current Tax Assets (Net)	72.00	32.00	72.00	32.00
(d) Other current assets	1,015.01	953.91	1,015.33	979.20
<b>Sub-total - Current assets</b>	<b>9,306.78</b>	<b>9,287.49</b>	<b>9,421.82</b>	<b>9,407.74</b>
<b>TOTAL - ASSETS</b>	<b>12,847.70</b>	<b>12,860.18</b>	<b>11,969.49</b>	<b>12,098.83</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
(a) Equity Share capital	2,104.06	2,104.06	2,104.06	2,104.06
(b) Other Equity	8,764.92	8,486.87	7,886.17	7,723.64
<b>Sub-total - Equity</b>	<b>10,868.98</b>	<b>10,590.93</b>	<b>9,990.23</b>	<b>9,827.70</b>
<b>Liabilities</b>				
<b>Non-current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	30.38	41.13	30.38	41.13
<b>Sub-total - Non-current liabilities</b>	<b>30.38</b>	<b>41.13</b>	<b>30.38</b>	<b>41.13</b>
<b>Current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	-	105.31	-	105.31
(ii) Trade Payables	1,329.51	1,318.18	1,329.93	1,318.60
(iii) Other Financial Liabilities	185.06	148.41	185.06	148.41
(b) Other Current Liabilities	326.71	223.81	326.71	223.93
(c) Provisions	107.06	432.41	107.18	433.75
<b>Sub-total - Current liabilities</b>	<b>1,948.33</b>	<b>2,228.12</b>	<b>1,948.87</b>	<b>2,230.00</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>12,847.70</b>	<b>12,860.18</b>	<b>11,969.49</b>	<b>12,098.83</b>



For ALPA LABORATORIES LIMITED

*Janu 2019*  
**PARESH CHAWLA**  
**MANAGING DIRECTOR**  
**DIN NO.00520411**